Tomivosertib
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Phase 2
Status
Terminated
Company
About eFFECTOR Therapeutics
eFFECTOR Therapeutics was founded to exploit dysregulated protein synthesis as a new therapeutic strategy in oncology. Its mission was to develop selective translation regulator inhibitors (STRIs) targeting the eIF4F complex, advancing two primary candidates, zotatifin and tomivosertib, into clinical trials for various solid tumors. The company's strategy was to move beyond targeting single mutations to disrupt the broader 'translationome' driving tumor growth and therapy resistance. Despite achieving key clinical milestones and raising significant capital as a public entity, eFFECTOR ultimately failed to secure further funding or partnerships, leading to its dissolution.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |